In a significant move set to reshape rapid diagnostics in the U.S., ASX-listed Lumos Diagnostics (ASX:LDX) has signed an exclusive six-year distribution agreement with PHASE Scientific, valued at up to US$317 million (A$487 million), for the supply of its flagship test, FebriDx®. Targeting a High-Growth Market The deal places Lumos’ FebriDx® at the forefront of
Read More
One of the punching bags of the ASX, Lumos Diagnostics (ASX: LDX), which develops diagnostics for healthcare professionals to more accurately diagnose and manage medical conditions, has announced the closure of its Sarasota manufacturing facility in Florida as they shift operations across the country to Carlsbad, California. The decision to close one of its sites
Read More
While small cap shareholders have become accustomed to major share price gains once a medtech or biotech receives FDA approval to commercialise their products, it’s not all sunshine and rainbows on the FDA horizon as Lumos Diagnostics (ASX: LDX) has found, following the rejection of their FebriDx test kits. As a rapid diagnostic test that
Read More
Rapid antigen tests (or lack thereof) have dominated the headlines for months now. Turning your kitchen counter into a mini pathology lab is now an essential ritual in determining if it’s the sniffles or the dreaded ‘c word’. Specialists in rapid point-of-care diagnostic technologies, Lumos Diagnostics (ASX: LDX) have been working on a useful test,
Read More
With ‘Rapid Antigen Test’ having only taken several days to likely be one of the most commonly used words of 2022, everyone is looking for them but demand is monumentally outweighing supply. With their surge in use, it may only be a matter of time until Australian regulators fast-track approval of more RAT manufacturers with
Read More
Having secured approval from regulators in Canada last month, Lumos Diagnostics (ASX: LDX) is set to dispatch the first orders of their rapid antigen test kit to the Maple nation with the initial orders valued at USD $250,000 (AUD $350,000). The orders are for Lumos’ CoviDx™ test kit which will enable qualified healthcare providers to
Read More